Research Correspondence

DOI: 10.4244/EIJ-D-24-00355

A new resorbable magnesium scaffold (DREAMS 3G): 12-month vasomotion results from the BIOMAG-I first-in-human study

Michael Haude1, MD, PhD; Juan F. Iglesias2, MD; Hector M. Garcia-Garcia3, MD, PhD; Dimitrios Barlagiannis1, MD; Sophie Degrauwe2, MD; Gebremedhin Melaku3, MD; Solomon Beyene3, MD; Ron Waksman3, MD

BIOMAG-I is a European, multicentre first-in-human study assessing the safety and performance of a third-generation sirolimus-eluting resorbable magnesium scaffold (DREAMS 3G, commercial name Freesolve [Biotronik AG]). This is a next-generation scaffold with improved radial support and stability, a reduced strut thickness, and an increased size portfolio compared to its precursor DREAMS 2G (Biotronik), while the resorption period of 12 months has been maintained1. This substudy measures drug-induced vasomotion after complete scaffold resorption at 12 months.

The study was approved by the centres’ ethics committees, and all patients provided additional informed consent for vasomotion assessments in 2 study centres. Endothelial-dependent vasomotor reactivity was estimated by selectively infusing incremental doses of acetylcholine (ACh) into the target coronary artery: ACh1 (low dose) 0.36 μg/ml, ACh2 (middle dose) 3.6 μg/ml, and ACh3 (high dose) 18 μg/ml. Each ACh concentration was infused at a speed of 2 ml/min for 3 minutes. Contrast injection and angiographic images were taken at the end of the ACh infusion for each concentration.

When the maximum tolerated ACh dose was administered, an intracoronary bolus injection of nitroglycerine (NTG, 200 μg) was...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 17
Sep 2, 2024
Volume 20 Number 17
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00044 Sep 16, 2024
Serial intracoronary imaging to predict efficacy and safety of magnesium-based resorbable scaffolds
Räber L and Kakizaki R
free
Trending articles
200.45

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
154.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
92.95

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
47.4

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
43.65

Clinical research

10.4244/EIJ-D-23-00590 Dec 4, 2023
Prognostic impact of cardiac damage staging classification in each aortic stenosis subtype undergoing TAVI
Nakase M et al
free
36.5

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
34.75

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved